ORPHA:494550
Squamous cell carcinoma of the larynx
Publications
10,335
95.8th percentile
Trials
133
Interventional, condition-specific
Researchers
1,137
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare head and neck tumor characterized by a malignant epithelial neoplasm with evidence of squamous differentiation, most commonly located in the supraglottis or glottis. The tumor can spread directly to adjacent structures or metastasize via lymphatic and blood vessels to regional lymph nodes, or lung, liver, and bones, respectively. Primary risk factors are tobacco smoking and (to a lesser extent) alcohol consumption. Patients may present with hoarseness, dyspnea, stridor, dysphagia, hemoptysis, or odynophagia.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005595
- UMLS:C0280324
- NCIT:C4044
Additional Mondo synonyms (9)
epidermoid carcinoma of larynx · epidermoid carcinoma of the larynx · laryngeal epidermoid carcinoma · laryngeal squamous cell carcinoma · laryngeal throat squamous cell cancer · larynx epidermoid carcinoma · larynx squamous cell carcinoma · squamous cell carcinoma of larynx · squamous cell carcinoma of the larynx
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
10,335 matched papers (6,508 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
133 matched on ClinicalTrials.gov (27 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
26
Drugs / clinical candidates · MONDO_0005595
- AVELUMAB·phase 3
- CAPECITABINE·phase 3
- CETUXIMAB·phase 3
- CISPLATIN·phase 3
- FLUOROURACIL·phase 3
- METHOTREXATE·phase 3
- PACLITAXEL·phase 3
- PANITUMUMAB·phase 3
- TISLELIZUMAB·phase 3
- TRETINOIN·phase 3
- VINFLUNINE·phase 3
- CAMRELIZUMAB·phase 2
- CARBOPLATIN·phase 2
- CONTUSUGENE LADENOVEC·phase 2
- DOCETAXEL·phase 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
10,335
10,335 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
10,335 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
6,508 in the last 10 years · high confidence · 95.8th percentile (publications denominator)
Phrase hits: 10,335 · MeSH hits: 0
Who's working on it?
1,137
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang X9 papers · 2026
Infectious Diseases Department, Weifang People's Hospital, Weifang, Shandong, China.
Papers in Europe PMC - 02chen X8 papers · 2026
Department of Nuclear Medicine, Daping Hospital, Army Medical University, Chongqing, China. xiaochen229@tmmu.edu.cn.
Papers in Europe PMC - 03Li Q8 papers · 2026
Department of Otolaryngology, People's Hospital of Henan Province, Zhengzhou City, 450003, China.
Papers in Europe PMC - 04Zhang S8 papers · 2026
First Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Papers in Europe PMC - 05Zhang H6 papers · 2026
Department of Otolaryngology, the Second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang, 050000, Hebei, China.
Papers in Europe PMC - 06Chen Z5 papers · 2026
Department of Otorhinolaryngology, Zhongshan Hospital Xiamen Branch, Fudan University, Xiamen, 361000, China; Xiamen Clinical Research Center for Cancer Therapy, Xiamen, 361000, China.
Papers in Europe PMC - 07Li Y5 papers · 2026
Department of Pathology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Papers in Europe PMC - 08Liu J5 papers · 2026
Department of First Clinical Medicine, Shanxi Medical University, Taiyuan, China.
Papers in Europe PMC - 09Liu M5 papers · 2026
The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China; Department of Otolaryngology Head and Neck Surgery, the Sixth Medical Center of Chinese PLA General Hospital, Beijing 100048, China; National Clinical Research Center for Otolaryngologic Diseases, Chinese PLA General Hospital, Beijing 100853, China; Department of Otolaryngology Head and Neck Surgery, Hainan Hospital of Chinese PLA General Hospital, Sanya 572013, China. Electronic address: mingbo666@vip.163.com.
Papers in Europe PMC - 10Liu X5 papers · 2026
The First Clinical Medical College of Lanzhou University, The First Hospital of Lanzhou University, Lanzhou 730000, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
133
interventional trials for this specific condition
133 interventional trials matched this specific condition name; 27 currently recruiting in our sample. 2,423 trials are registered for squamous cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
133 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 98.8th percentile).
high confidence · 98.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
133 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05136196·RECRUITING·BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Not reviewed·Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage IV Cutaneous Melanoma AJCC v8 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8·Matched via name phrase
- NCT07423078·RECRUITING·Window of Opportunity in Preserving Laryngeal Function Trial
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) · Locally Advanced Laryngeal Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT06137378·RECRUITING·European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
Not reviewed·Conditions: Squamous Cell Carcinoma of Head and Neck · Hypopharyngeal Squamous Cell Carcinoma · Laryngeal Squamous Cell Carcinoma Stage III · Laryngeal Squamous Cell Carcinoma Stage IV·Matched via name phrase
- NCT06636734·RECRUITING·Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary · Metastatic Head and Neck Squamous Cell Carcinoma · Metastatic Hypopharyngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT04754321·RECRUITING·Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
Not reviewed·Conditions: Head and Neck Carcinoma of Unknown Primary · Locally Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma · Recurrent Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT06980038·RECRUITING·Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma · Laryngeal Squamous Cell Carcinoma · Nasal Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT05172245·RECRUITING·Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Not reviewed·Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Carcinoma of Unknown Primary · Locally Advanced Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06532279·RECRUITING·Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Not reviewed·Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06589804·RECRUITING·Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Not reviewed·Conditions: Metastatic Head and Neck Squamous Cell Carcinoma · Metastatic Hypopharyngeal Squamous Cell Carcinoma · Metastatic Laryngeal Squamous Cell Carcinoma · Metastatic Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT01473784·RECRUITING·Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Not reviewed·Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity · Recurrent Mucoepidermoid Carcinoma of the Oral Cavity · Recurrent Squamous Cell Carcinoma of the Hypopharynx · Recurrent Squamous Cell Carcinoma of the Larynx·Matched via name phrase
- NCT05144698·RECRUITING·RAPA-201 Therapy of Solid Tumors
Not reviewed·Conditions: Solid Tumor · Small Cell and Non-small Cell Lung Cancer · Head and Neck Cancer · Squamous Cell Carcinoma of Oral Cavity·Matched via name phrase
- NCT05333523·RECRUITING·Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.
Not reviewed·Conditions: Laryngeal Squamous Cell Carcinoma · Hypopharynx Squamous Cell Carcinoma · Oropharyngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT06611137·RECRUITING·SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Not reviewed·Conditions: Laryngeal Cancer · Hypopharynx Cancer·Matched via name phrase
- NCT07063212·RECRUITING·A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Not reviewed·Conditions: Squamous Cell Carcinoma of Head and Neck · Sinus Cancer · Nasal Cavity Cancer · Oral Cavity Cancer·Matched via name phrase
Broader category: squamous cell carcinoma
2,423
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06540443·RECRUITING·Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Lymph Node Metastasis·Matched via name phrase
- NCT06599775·NOT YET RECRUITING·Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Not reviewed·Conditions: Resectable Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07173270·NOT YET RECRUITING·Improved Oral Health in Head and Neck Cancer Survivors
Not reviewed·Conditions: Head and Neck Cancer Squamous Cell Carcinoma · Head and Neck Cancer·Matched via name phrase
- NCT07487896·RECRUITING·A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Not reviewed·Conditions: Advanced Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06659146·RECRUITING·Thermotherapy in Addition to SOC Palliative Radiotherapy
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma · Breast Cancer Recurrent·Matched via name phrase
- NCT07726199·RECRUITING·Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
Not reviewed·Conditions: Oral Squamous Cell Carcinoma (OSCC)·Matched via name phrase
- NCT06589609·RECRUITING·Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Not reviewed·Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT06915454·RECRUITING·High-Resolution PET-CT Imaging for Surgical Margin Visualization
Not reviewed·Conditions: Cancer · Solid Malignant Tumors · SCC - Squamous Cell Carcinoma · HNSCC·Matched via name phrase
- NCT06693323·RECRUITING·Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Not reviewed·Conditions: HNSCC · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07629817·NOT YET RECRUITING·Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06648096·RECRUITING·Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Not reviewed·Conditions: Fanconi Anemia · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT05747625·RECRUITING·(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck·Matched via name phrase
- NCT06492460·RECRUITING·2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Squamous Cell Carcinoma of Head and Neck·Matched via name phrase
- NCT07337161·RECRUITING·Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma
Not reviewed·Conditions: Cutaneous · Head and Neck Cancer Squamous Cell Carcinoma·Matched via name phrase
Observational and natural-history studies
7 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06380686·RECRUITING·Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Not reviewed·Conditions: Squamous Cell Carcinoma of the Oral Cavity · Squamous Cell Carcinoma of the Oropharynx · Squamous Cell Carcinoma of the Hypopharynx · Squamous Cell Carcinoma of the Larynx·Matched via name phrase
- NCT06947668·RECRUITING·Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
Not reviewed·Conditions: Squamous Cell Carcinoma of Oropharynx · Squamous Cell Carcinoma of the Hypopharynx · Larynx Squamous Cell Carcinoma · Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 24 · after dedupe 24 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 24 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (24)
- ctis·2024-519750-36-00·Authorised, ongoing·The STELLAR trial: Fluorescence-guided surgery in laryngeal- and hypopharyngeal cancer: a feasibility trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15819396·Recruiting·A Phase I/IIa trial of KJ-103 in solid cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11941599·Recruiting·JNJ-90301900 (NBTXR3) activated by radiotherapy with or without cetuximab in LA-HNSCC
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14471479·Recruiting·How mouth bacteria affect radiation treatment for head and neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14681287·No longer recruiting·Can we use ultrasound to assess the structure and size of important speech and swallowing muscles before and after radiotherapy ?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98745687·No longer recruiting·A Phase Ib/II, open-label study of amivantamab monotherapy and amivantamab in addition to other therapeutic agents in participants with head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN63646763·No longer recruiting·A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66274524·No longer recruiting·Accelerating the development and implementation of DNA damage inhibitor and radiotherapy treatment (with or without immunotherapy) in head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN93840508·Stopped·Hyperbaric radiation sensitization of head and neck cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89314418·Stopped·Cetuximab immunotherapy combination in head and neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14224600·No longer recruiting·LiTEFORM light therapy effectiveness for oral mucositis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76291951·No longer recruiting·WISTERIA: WEE1 inhibitor with cisplatin and radiotherapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN44435485·No longer recruiting·Accelerated hypofractionation, Chemotherapy, Intensity Modulation and Evaluation of Dose Escalation in Oropharyngeal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN87302591·No longer recruiting·Effect of a topical treatment on skin when having chemotherapy and radiotherapy to the head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74465582·No longer recruiting·Trial of Induction TPF therapy in Advanced head & Neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN87356938·No longer recruiting·Radiotherapy (intensity-modulated radiation therapy [IMRT]), Erbitux® And CHemotherapy for unresectable carcinomas of head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN52466525·No longer recruiting·Phase III trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN47339346·No longer recruiting·Phase I-/II-study of Hyperfractionated-Accelerated Radiation Therapy plus Cetuximab plus Cisplatin chemotherapy in locally advanced inoperable squamous cell cancers of head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72086307·No longer recruiting·Post-OPerative Accelerated RadioTherapy versus conventional radiotherapy in squamous cell head and neck cancer: a phase III randomised study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN06768231·No longer recruiting·The effect of comprehensive counseling by a nurse specialist on depressive symptoms and quality of life: a prospective randomised study in patients with head and neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN86478952·No longer recruiting·A randomised two arm trial of modestly accelerated radiotherapy with synchronous cisplatinum chemotherapy versus conventional radiotherapy with synchronous cisplatinum chemotherapy in the treatment of head and neck squamous cell carcinoma: a pilot study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17541410·No longer recruiting·EaStER: Early Stage glottic laryngeal cancer: Endoscopic excision or Radiotherapy? - a feasibility study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76747656·No longer recruiting·A phase II randomised study of cisplatinum and nifedipine in end stage carcinoma of the head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN68133429·No longer recruiting·A trial comparing conventional fractionation with 'CHART' in the treatment of head and neck cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the larynx — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the larynx" OR "Squamous cell carcinoma of larynx" OR "epidermoid carcinoma of larynx" OR "epidermoid carcinoma of the larynx" OR "laryngeal epidermoid carcinoma" OR "laryngeal squamous cell carcinoma" OR "laryngeal throat squamous cell cancer" OR "larynx epidermoid carcinoma" OR "larynx squamous cell carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the larynx" OR "Squamous cell carcinoma of larynx" OR "epidermoid carcinoma of larynx" OR "epidermoid carcinoma of the larynx" OR "laryngeal epidermoid carcinoma" OR "laryngeal squamous cell carcinoma" OR "laryngeal throat squamous cell cancer" OR "larynx epidermoid carcinoma" OR "larynx squamous cell carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 133 interventional · 7 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"squamous cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T17:33:40.994Z
